Oric Pharmaceuticals, Inc. (ORIC)
13.17
-0.46
(-3.37%)
USD |
NASDAQ |
Oct 23, 16:00
13.16
-0.01
(-0.08%)
After-Hours: 20:00
Oric Pharmaceuticals Enterprise Value : 1.103B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 1.103B |
| October 22, 2026 | 1.151B |
| October 21, 2026 | 1.174B |
| October 20, 2026 | 1.167B |
| October 19, 2026 | 1.057B |
| October 16, 2026 | 1.018B |
| October 15, 2026 | 1.062B |
| October 14, 2026 | 939.71M |
| October 13, 2026 | 910.69M |
| October 12, 2026 | 962.51M |
| October 09, 2026 | 981.16M |
| October 08, 2026 | 985.31M |
| October 07, 2026 | 983.24M |
| October 06, 2026 | 980.13M |
| October 05, 2026 | 1.033B |
| October 02, 2026 | 1.003B |
| October 01, 2026 | 1.036B |
| September 30, 2026 | 1.135B |
| September 29, 2026 | 1.124B |
| September 28, 2026 | 1.114B |
| September 25, 2026 | 1.102B |
| September 24, 2026 | 1.104B |
| September 23, 2026 | 1.120B |
| September 22, 2026 | 1.138B |
| September 21, 2026 | 1.052B |
| Date | Value |
|---|---|
| September 18, 2026 | 1.064B |
| September 17, 2026 | 1.073B |
| September 16, 2026 | 1.038B |
| September 15, 2026 | 1.020B |
| September 14, 2026 | 1.050B |
| September 11, 2026 | 986.35M |
| September 10, 2026 | 989.46M |
| September 09, 2026 | 1.034B |
| September 08, 2026 | 1.046B |
| September 04, 2026 | 1.071B |
| September 03, 2026 | 1.059B |
| September 02, 2026 | 1.099B |
| September 01, 2026 | 1.074B |
| August 31, 2026 | 1.085B |
| August 28, 2026 | 1.111B |
| August 27, 2026 | 1.163B |
| August 26, 2026 | 1.180B |
| August 25, 2026 | 1.172B |
| August 24, 2026 | 1.134B |
| August 21, 2026 | 1.210B |
| August 20, 2026 | 1.177B |
| August 19, 2026 | 1.257B |
| August 18, 2026 | 1.181B |
| August 17, 2026 | 1.125B |
| August 14, 2026 | 1.176B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.514B |
| Alnylam Pharmaceuticals, Inc. | 29.64B |
| Anika Therapeutics, Inc. | 273.50M |
| Savara, Inc. | 724.16M |
| Vericel Corp. | 2.108B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -41.49M |
| Total Expenses (Quarterly) | 41.49M |
| EPS Diluted (Quarterly) | -0.3841 |
| Earnings Yield | -10.25% |
| Normalized Earnings Yield | -10.25 |